Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 8;14:4762. doi: 10.1038/s41467-023-40436-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Schematics showing the sites of vector injections in the striatum in Monkey E. AAV2.1-A-Syn-GFP vector into the caudate nucleus and the same vector at a higher-titer (Syn-GFP, high) into the putamen on one side, and AAV2-CMV-GFP vector into the caudate nucleus and AAV2-Syn-GFP vector into the putamen on the other side. b Representative PET images overlaid on MR images showing [¹¹C]DCZ-specific binding taken before (Pre) or at 80 and 184 days after the vector injections. Each value of binding potential is expressed as the regional binding potential relative to a nondisplaceable radioligand in tissue (BP_ND). c Time-dependent changes of [¹¹C]DCZ-specific binding at the sites of vector injections. Values before the injections, corresponding to (Pre) in b, are plotted at Day 0. d Representative PET&MR-fused images showing normalized [¹⁸F]FDG uptake following vehicle administration (Control) or DCZ administration at 86 and 193 days after the vector injections. Each value of FDG uptake is expressed as the standardized uptake value ratio (SUVR) to the mean value of the whole brain, averaged between 60 and 90 min after the radioligand injection. e Schematics showing the sites of vector injections in Monkey F. AAV2-Syn-GFP vector into the caudate nucleus and AAV2.1-A-Syn-GFP vector into the putamen on one side, and AAV2 vector with Syn promoter but without GFP tag (AAV2-Syn) into the caudate nucleus and AAV1-Syn-GFP vector into the putamen on the other side. f Representative PET images overlaid on MR images showing [¹¹C]DCZ-specific binding taken before (Pre) or at 64 and 358 days after the vector injections. g Time-dependent changes of [¹¹C]DCZ-specific binding at the sites of vector injections. Values before the injections are plotted at Day 0. h Representative PET&MR-fused images showing normalized [¹⁸F]FDG uptake following vehicle administration or DCZ administration at 72 and 365 days after the vector injections. Source data are provided in this paper. Schematics in a and e were reproduced from Paxinos G. et al. ⁵⁷. (This article was published in Academic Press, Copyright Elsevier (2009)).